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Tea-induced improvement of 
endothelial function in humans: 
No role for epigallocatechin gallate 
(EGCG)
Mario Lorenz1,5, Franziska Rauhut1, Christine Hofer1, Stefanie Gwosc1, Eda Müller1, Damaris 
Praeger1, Benno F. Zimmermann2,3, Klaus-Dieter Wernecke4, Gert Baumann1, Karl Stangl1 & 
Verena Stangl1,5
Consumption of tea is inversely associated with cardiovascular diseases. However, the active 
compound(s) responsible for the protective effects of tea are unknown. Although many favorable 
cardiovascular effects in vitro are mediated by epigallocatechin gallate (EGCG), its contribution to the 
beneficial effects of tea in vivo remains unresolved. In a randomised crossover study, a single dose of 
200 mg EGCG was applied in three different formulas (as green tea beverage, green tea extract (GTE), 
and isolated EGCG) to 50 healthy men. Flow-mediated dilation (FMD) and endothelial-independent 
nitro-mediated dilation (NMD) was measured before and two hours after ingestion. Plasma levels of 
tea compounds were determined after each intervention and correlated with FMD. FMD significantly 
improved after consumption of green tea containing 200 mg EGCG (p < 0.01). However, GTE and EGCG 
had no significant effect on FMD. NMD did not significantly differ between interventions. EGCG plasma 
levels were highest after administration of EGCG and lowest after consumption of green tea. Plasma 
levels of caffeine increased after green tea consumption. The results show that EGCG is most likely 
not involved in improvement of flow-mediated dilation by green tea. Instead, other tea compounds, 
metabolites or combinations thereof may play a role.
Consumption of tea is associated with reduced progression of atherosclerosis and lower cardiovascular mor-
tality1, 2. However, the substance(s) mediating the favorable cardiovascular effects of tea in vivo have not yet 
been identified. Tea contains high amounts of polyphenols with significant biological activities. The green tea 
catechin epigallocatechin gallate (EGCG) is the physiologically most active compound in vitro3. A large number 
of in vitro studies and animal experiments provide evidence of the beneficial effects of EGCG on cardiovascular 
parameters4, 5. Stimulation of nitric oxide (NO) production by endothelial cells and subsequent NO-dependent 
vasodilation in isolated vessels are two of the most prominent cardiovascular actions of EGCG in vitro6–8. Owing 
to promising results at the cellular level, EGCG has become extensively applied in human intervention studies. 
More than 80 studies with EGCG, which encompass a wide range of clinical applications, were registered on clin-
icaltrials.gov as of October 2016. It is largely unknown, however, whether the beneficial cardiovascular effects of 
EGCG in vitro can be reproduced in humans.
To elucidate this matter, we investigated the contribution of EGCG to tea-induced changes in flow-mediated 
dilation (FMD). Impaired endothelial function represents an early marker for later cardiovascular events9. It had 
been previously shown that consumption of green tea10 as well as of black tea11 improved FMD in humans. A 
recent meta-analysis demonstrated that short- and long-term tea consumption increases endothelial-dependent 
vasodilation12. The role of single tea compounds, and especially of EGCG, to the described cardiovascular effects, 
however, remains unclear. We studied the impact of a single dose of EGCG in three different application forms 
(green tea beverage, GTE, and isolated EGCG) on FMD in healthy volunteers. The amount of ingested EGCG 
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(200 mg) corresponds to approx. 0.5 l of green tea. The results provide insights into the potential role of EGCG 
and other tea compounds in the beneficial cardiovascular effects of green tea in vivo.
Results
Interventions had no influence on plasma levels of cardiovascular risk markers. A total of 207 
men responded, and interviews were conducted with these volunteers to assess for eligibility. 56 subjects fulfilled 
the inclusion criteria, including the time requirements, and were enrolled in the study. Four participants were 
excluded during the study for having blood lipid levels outside the normal range. Two subjects dropped out for 
personal reasons. 50 subjects finished the study. A flow chart of the study is shown in Fig. 1. Table 1 summarizes 
the baseline characteristics of the study population. Subjects consumed a single dose of 200 mg EGCG as green 
tea beverage, as GTE, or as isolated EGCG. FMD was measured before and two hours after ingestion. To prevent 
food intake from interfering with EGCG absorption and FMD, the interventions were done in a fasting state. The 
composition of the interventions is shown in Table 2. Levels of LDL, HDL, total cholesterol, TG and CrP did not 
significantly change two hours after the interventions (Wilcoxon test, data not shown).
Only green tea improved FMD. Before interventions, there were no statistical differences in baseline 
vessel diameter, in FMD, and in NMD between the four study arms by repeated measures ANOVA (Table 3). 
Hot water decreased FMD non-significantly by −0.84% (5.05 ± 2.65% at baseline and 4.21 ± 2.65% after two 
hours, p = 0.076, paired t-test). Green tea significantly improved FMD by 1.36% (4.49 ± 2.77% at baseline and 
5.85 ± 3.61% after two hours, p = 0.004, paired t-test). GTE and EGCG, although containing the same amount of 
EGCG as the tea beverage, had no significant effect on FMD (GTE: 4.72 ± 3.16% at baseline and 4.90 ± 3.04% after 
two hours, p = 0.679, paired t-test; EGCG: 5.00 ± 3.07% at baseline and 4.77 ± 3.99% after two hours, p = 0.648, 
paired t-test). Between treatments, there were significant overall differences in changes of FMD (p = 0.006, 
repeated measures ANOVA). After post hoc Bonferroni analysis, only green tea significantly improved FMD 
compared to water (Fig. 2). No significant changes in FMD were observed between the other treatments. The 
Figure 1. Flow-chart of the study.
Mean SD
Age (years) 33.9 7.6
SBP (mm Hg) 122.0 9.4
DBP (mm Hg) 69.7 7.6
BMI (kg/m2) 23.7 2.5
HbA1c (%) 5.2 0.3
Homocysteine (µM) 11.3 4.7
CrP (mg/l) 1.2 2.1
Total cholesterol (mg/dl) 178.7 34.2
HDL cholesterol (mg/dl) 54.3 11.4
LDL cholesterol (mg/dl) 112.2 34.2
TG (mg/dl) 93.2 51.1
Lipoprotein(a) (mg/l) 153.2 277.7
Table 1. Baseline characteristics of the study population (n = 50). SD, standard deviation; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; BMI, body mass index; CrP, C-reactive protein; TG, triglycerides.
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overall effects on FMD increased with increasing complexity of the interventions – i.e., with an increasing num-
ber of compounds contained in the interventions (Fig. 2). There were significant overall differences in absolute 
FMD by repeated measures ANOVA two hours after ingestion between treatments (p = 0.032). After Bonferroni 
post hoc analysis, the absolute FMD differed significantly only between green tea and water (5.85 ± 3.61% after 
tea and 4.21 ± 2.65% after water, p = 0.017), whereas no significant differences were observed between the other 
interventions. The net response in FMD between green tea and water (mean FMD after green tea minus mean 
FMD after hot water as control) was 1.64%.
NMD was not affected by the interventions. Changes in endothelial-independent NMD did not signif-
icantly differ between interventions (water: −0.32 ± 5.42%, EGCG: −0.15 ± 4.78%, GTE: −0.36 ± 4.71%, green 
tea: −0.79 ± 5.00%; p = 0.92, repeated measures ANOVA), and did not coincide with FMD.
EGCG plasma levels did not correlate with changes in FMD. Plasma levels of EGCG and of the other 
tea catechins were below detection limits before interventions and after consumption of hot water (data not 
shown). The highest EGCG plasma levels were observed after intake of isolated EGCG and the lowest after con-
sumption of green tea. Administration of GTE resulted in intermediate EGCG plasma levels (Fig. 3a). EGCG was 
present in the free (unconjugated) form in human plasma, in agreement with previous studies13. No significant 
correlations between EGCG plasma levels and changes in FMD were observed for all interventions (Fig. 3b).
TB GA caffeine GC Catechin GCG EC ECG EGC EGCG
Green tea (mg/l) 15.0 35.4 265 113 10.8 7.8 51.6 89.1 141 452.5
GTE (mg/g) <0.01 13.2 7.1 <0.01 6.5 16.5 69.5 70.5 145 492.3
EGCG (mg/g) <0.01 0.5 0.04 <0.01 0.7 <0.01 5.0 40.6 <0.01 936.0
Table 2. Composition of the interventions. TB, theobromine; GA, gallic acid; GC, gallocatechin; GCG, 
gallocatechin gallate; EC, epicatechin; ECG, epicatechin gallate; EGC, epigallocatechin; EGCG, epigallocatechin 
gallate; GTE, green tea extract.
Water EGCG GTE Green Tea
Baseline diameter FMD (mm) 4.07 (0.49) 4.08 (0.51) 4.05 (0.48) 4.11 (0.51) n.s.
FMD (%) 5.05 (2.65) 5.00 (3.07) 4.72 (3.16) 4.49 (2.77) n.s.
Baseline diameter NMD (mm) 4.06 (0.50) 4.06 (0.53) 4.08 (0.48) 4.08 (0.50) n.s.
NMD (%) 19.57 (6.40) 18.19 (5.59) 18.82 (6.07) 19.70 (6.14) n.s.
Table 3. Baseline diameter and baseline FMD and NMD before interventions. FMD, flow-mediated dilation; 
NMD, nitro-mediated dilation; GTE, green tea extract; baseline diameter, diameter of artery brachialis before 
hyperaemic stimulus or application of nitroglycerine. n.s.; no significant differences by repeated measures 
ANOVA. Values are mean (SD) from n = 50 subjects.
Figure 2. Only green tea increased flow-mediated dilation (FMD). Subjects consumed 200 mg of EGCG as 
isolated EGCG, GTE, or green tea after fasting overnight. An equal volume of hot water served as control. Green 
tea significantly increased FMD compared to GTE, EGCG, and water as control. Water slightly decreased FMD, 
whereas EGCG and GTE had little effects. Data are means ± SEM from n = 50 subjects. All p-values by repeated 
measures ANOVA followed by post hoc Bonferroni.
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No correlations of catechin plasma levels with FMD. Beneficial effects on endothelial function have 
also been described for epicatechin (EC)14. EC plasma levels were higher after GTE and lower after green tea 
(Fig. 4a), and no correlation with changes in FMD was observed after green tea consumption (Fig. 4b). Similar 
results were obtained for epigallocatechin (EGC) (Fig. 4a,b). Mean plasma concentrations for epicatechin gallate 
(ECG) were very low, and a negative correlation with changes in FMD after green tea was observed (Fig. 4a,b). 
The sum of all catechins (total catechin plasma levels) showed a non-significant negative correlation with changes 
in FMD after tea (r = −0.239, p = 0.095, Spearman’s). An overview of catechin plasma levels after the interven-
tions before and after deconjugation is given in Table 4.
Caffeine plasma levels increased after green tea consumption. Since catechin plasma levels were 
not sufficient to account for differential effects on FMD between interventions, we measured blood levels of 
additional tea compounds. Plasma levels of caffeine markedly increased two hours after consumption of green 
tea, whereas a slight decrease was observed in the other interventions (Fig. 5a). Plasma levels of theobromine 
slightly decreased after all interventions (Fig. 5a). Caffeine and theobromine were also present at baseline (before 
intervention) in all treatments. We observed a slight, but significant positive correlation between plasma concen-
trations of caffeine and changes in FMD after green tea consumption, whereas plasma levels of theobromine did 
not correlate with FMD (Fig. 5b).
Discussion
This study shows for the first time that EGCG is most likely not involved in tea-induced improvement of endothe-
lial function in humans. Although EGCG plasma levels were highest after intake of EGCG and lowest after 
consumption of green tea, only green tea improved FMD. It has been consistently demonstrated that green tea 
improves endothelial function in humans10, 15, 16. The results of our study confirmed these findings. Although not 
statistically significant, a minor effect on FMD was also observed for GTE in our study.
Green tea and EGCG stimulated NO production in endothelial cells by activating endothelial nitric oxide 
synthase (eNOS) and induced vasodilation in aortic rings10, 17. However, the contribution of EGCG to the effects 
of green tea in vivo remains elusive. In our study, we observed no effect of 200 mg isolated EGCG on endothelial 
function in humans. Widlansky et al. found an acute (but not long-term) improvement in FMD with 300 mg 
EGCG in patients with coronary artery disease18. However, apart from different EGCG doses used, in contrast 
Figure 3. EGCG plasma levels did not correlate with changes in FMD. Shown are the sum of free and 
conjugated EGCG plasma levels two hours after consumption (a). Data are means ± SEM from n = 50 subjects 
for water, EGCG, and green tea and n = 49 for GTE. *p < 0.05 versus GTE and green tea, #p < 0.05 versus EGCG 
and green tea (Wilcoxon test). Correlations of EGCG plasma levels with changes in FMD after green tea, GTE, 
and EGCG (b). There were no significant correlations between EGCG plasma levels and FMD for all treatments 
(Spearman’s). Data are from n = 50 subjects for EGCG and green tea and n = 49 for GTE.
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to our study Widlansky et al. observed no differences in the absolute FMD between EGCG and placebo after 
supplementation. A numerical lower baseline FMD before EGCG as compared to before placebo could have con-
tributed to their results. In vitro, significant effects of EGCG on NO production and vasodilation were obtained 
only at concentrations of 1 µM or higher6–8, concentrations that were not achieved in plasma in our study and in 
Widlansky et al.18. Surprisingly, mean plasma levels of EGCG in our study were inversely associated with changes 
in FMD between interventions (Fig. 6). All of the above results make a substantial contribution of EGCG to the 
vasodilating effects of green tea in vivo very unlikely.
Stimulation of endothelial NO production and vasodilation in isolated vessels have also been described 
for EC8, 19. In a small study by Schroeter et al., the administration of 1–2 mg/kg body weight of EC resulted in 
improved FMD in three subjects14. However, EC supplementation for 4 weeks (100 mg/d) had no significant 
effects on FMD in 35 subjects20. Consumption of 442 ml green tea in our study resulted in the intake of 23 mg EC, 
which is much less than the amount of EC ingested in the study by Schroeter et al. EC plasma levels in our study 
were very low and did not parallel changes in FMD between interventions. In line with previous reports13, EC 
was fully conjugated and not present in the free form in plasma. Therefore, the involvement of EC in the effects 
of green tea on FMD is rather unlikely. Mean plasma levels of the other catechins ECG and EGC were also very 
low and showed no correlations with FMD, indicating that both catechins are in all likelihood not involved in the 
improvement of FMD by green tea. Also, the sum of all catechins showed no correlation with FMD.
What other compounds could potentially contribute to the effects of green tea? Caffeine is present in high 
amounts in green and black tea. Consequently, plasma levels of caffeine substantially increased after consumption 
Figure 4. No correlations of catechin plasma levels with changes in FMD. Plasma levels of EC (epicatechin), 
EGC (epigallocatechin), and ECG (epicatechin gallate) after hydrolysis (sum of free and conjugated catechins) 
two hours after consumption (a). The scale of the y axes are equal to Fig. 3 to facilitate comparisons with 
EGCG levels. Data are means ± SEM from n = 50 subjects for water, EGCG, and green tea and n = 49 for GTE. 
Correlations of catechin plasma levels with FMD changes after tea consumption (b). Non-significant negative 
correlations were observed between catechin plasma levels and FMD changes (Spearman’s). Data are from 
n = 50 subjects.
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Table 4. Catechin plasma levels before and after hydrolysis (deconjugation) 2 hours after interventions. EC, 
epicatechin; ECG, epicatechin gallate; EGC, epigallocatechin; EGCG, epigallocatechin gallate; n.d. not detectable; 
n.q. not quantifiable. Data are mean (SD) from n = 50 subjects for green tea and EGCG and n = 49 for GTE.
Figure 5. Caffeine but not theobromine plasma levels correlate with FMD changes after green tea consumption. 
Plasma levels of caffeine and theobromine before and two hours after interventions (a). For comparison, the scale 
is identical for both compounds. Data are means ± SEM from n = 50 subjects for water, EGCG, and green tea 
and n = 49 for GTE. Significant positive correlations between plasma levels and changes in FMD after green tea 
consumption were obtained for caffeine, but not for theobromine (Spearman’s) (b). Data are from n = 50 subjects.
Figure 6. Inverse relationship between FMD and EGCG plasma levels after the interventions. FMD gradually 
increased with the number of compounds present (i.e., with the complexity) of the intervention (upper panel), 
but EGCG plasma levels are inversely proportional.
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of green tea in our study. However, the published data on the role of caffeine on flow-mediated dilation are con-
flicting. A cup of decaffeinated coffee had no effect on FMD in healthy adults, whereas caffeinated coffee (with 
80 mg of caffeine) even declined FMD21. In a similar study, decaffeinated coffee resulted in a slight increase in 
FMD, whereas caffeinated coffee significantly decreased FMD in healthy subjects22. Consumption of green tea 
significantly improved FMD, however, the corresponding amount of caffeine contained in this tea (125 mg) did 
only slightly increase FMD16. Likewise, a significant improvement of FMD was observed two hours after con-
sumption of black tea, but an equivalent dose of 200 mg caffeine had no effect11. But there is also evidence that caf-
feine exerts beneficial effects on endothelial function. A single dose of caffeine acutely improved FMD in patients 
with stable CAD, and increased forearm blood flow23, 24. Chronic coffee consumption was associated with higher 
FMD25, and moderate coffee consumption resulted in a decreased risk of cardiovascular diseases26. An improved 
FMD was also observed after administration of a green tea extract containing caffeine27. In addition, an inverse 
association with risk of CVD and stroke was shown for higher coffee and green tea consumption28. Tea (mainly 
black) as well as moderate coffee consumption have been shown to decrease the risk for coronary heart disease2. 
Taken together, these studies point to a cardiovascular risk reduction for both tea and coffee.
In black tea, the amount of EGCG (and of other catechins) is much lower compared to green tea, depending 
on the degree of fermentation. Theaflavins and thearubigins, the major polyphenolic compounds in black tea, are 
too large for substantial absorption into the circulation29. Green and black tea are, however, equally effective in the 
improvement of FMD10, 12, and both teas contain a similar amount of caffeine. However, other compounds includ-
ing plasma metabolites of tea polyphenols, such as methylated compounds/phase I-breakdown or gut microbial 
metabolites (in addition to glucuronidated and sulphated substances), could also be involved. Although EGCG 
can be methylated30, very low31, or no methylated (or otherwise metabolised) EGCG32 was found in human 
plasma after consumption of a green tea extract or green tea. An inverse association between the degree of uri-
nary flavonoid O-methylation (4OMGA) and FMD after consumption of black tea indicates that methylation of 
tea flavonoids could rather affect endothelial function33. However, the influence of other (as yet unknown) phase 
I-breakdown or gut microbial metabolites on tea-induced FMD cannot be fully excluded.
Some study limitations should be acknowledged. The observed correlation between caffeine plasma levels and 
FMD is only weak and does not prove a role of caffeine in tea-induced endothelial function. A study with caffeine 
and hot water, EGCG and green tea or with caffeinated and decaffeinated green tea would be required to verify 
the role of caffeine in tea-induced FMD. Although EGCG did not mediate the effects of green tea on FMD in our 
study with healthy subjects, a contribution of EGCG to tea-mediated improvements of endothelial dysfunction 
cannot be fully excluded. Even though the amount of EGCG used in our study (200 mg) corresponds to a nutri-
tionally relevant dose that can be consumed by drinking tea, it does not necessarily reflect habitual tea drinking of 
several cups per day. Also, it should be noted that the contributions of single tea compounds to tea-induced FMD 
cannot be generalised for other cardiovascular, neurological, or anti-tumor effects of green tea.
In summary, our data indicate that EGCG is not involved in changes of FMD by green tea. The lack of an 
impact of EGCG on tea-induced improvements in endothelial function clearly points out that caution is indicated 
when translating promising in vitro experiments using a single isolated compound from a food matrix into the 
human situation. In light of many ongoing human studies with EGCG it will be of considerable interest to study 
the contribution of this promising in vitro candidate to other putative beneficial health effects of green tea.
Methods
Study population. Healthy men between 20 and 50 years were recruited by press advertisements. Subjects 
with chronic diseases and known cardiovascular risk factors such as high blood cholesterol (≥240 mg/dl), dia-
betes, arterial hypertension, and body mass index >27 kg/m2 were excluded. Plasma lipid profiles and blood 
pressure were required to be within the normal range for study inclusion. Regular tea consumption, current 
smoking, chronic drug use, and alcohol abuse were additional exclusion criteria. The study was approved by the 
Charité University Hospital Ethics Committee and participants provided their written informed consent. The 
study protocol was in accordance to local university guidelines and with the principles outlined in the Declaration 
of Helsinki.
Study design. This pilot study was a prospective, exploratory, randomised, crossover study. A single dose 
of 200 mg of EGCG was orally ingested in different application forms. After fasting overnight, each subject con-
sumed 200 mg of EGCG on different days, either as green tea beverage, green tea extract (GTE), or purified 
EGCG. The same amount of hot water was applied with each of the EGCG forms ingested. The corresponding 
amount of hot water served as control. Randomization was performed using computer-generated random num-
bers for the order of treatments. The interventions were at least 3 days apart. Before and two hours after ingestion, 
flow-mediated and nitro-mediated dilation of the brachial artery was assessed by vascular ultrasound. Blood 
was taken before and two hours after intervention, and plasma levels of tea compounds were measured. The 
study was performed at the Department of Cardiology and Angiology (Campus Mitte) at Charité – University 
Medicine Berlin, Germany. The study has been registered under ClinicalTrials.gov https://clinicaltrials.gov/ct2/
show/NCT01662232, registration No. NCT01662232; date of registration: August 7, 2012.
Interventions. Darjeeling green tea was obtained from King’s Teagarden, Berlin, Germany. For determi-
nation of the EGCG content of the beverage before the start of the study, 6.75 grams of ground tea solids were 
brewed with 550 ml of boiling water for 3 min. The infusion had an EGCG content of 452.5 ± 8.7 mg/l (mean ± SD, 
n = 6). For administration of 200 mg of EGCG, the participants consumed 442 ml of the beverage. The GTE was 
supplied by Nutri-Fit GmbH & Co. KG. The EGCG content of the extract was 492.3 ± 1.4 mg/g (n = 3). For inges-
tion of 200 mg of EGCG, the subjects took a capsule containing 406.3 mg of GTE. The purity of the EGCG (kindly 
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provided by Nutri-Fit GmbH & Co. KG) as determined by HPLC prior to the study was 93.6 ± 1.3% (n = 3). To 
correct for EGCG content, the subjects took a capsule containing 214 mg of EGCG for ingestion of 200 mg EGCG. 
An equal amount of hot water (442 ml, according to the volume of the beverage) was applied together with all 
capsules. 442 ml of hot water served as control.
Assessment of flow-mediated (FMD) and nitro-mediated dilation (NMD). Endothelium-dependent 
FMD was assessed by measuring the change in brachial artery diameter during reactive hyperemia after 
cuff occlusion of the forearm, according to established guidelines34. Endothelial function was measured by 
high-resolution vascular ultrasound using Vivid 7 (General Electric Medical Systems) with a 12-MHz linear array 
transducer. We performed all measurements in the morning at the same time of the day. Data were analysed using 
the automatic edge detection software FMD Studio Cardiovascular Suite (CVS 2.0, QUIPU, Pisa, Italy), which 
analyses the data in real time35. Baseline diameter was assessed for 1 min, followed by 5 min of cuff occlusion and 
determination of diameter changes after reactive hyperemia for 4 min after cuff release. FMD was defined as the 
maximum percentage change in diameter compared with baseline measurements. Percent changes in FMD of the 
brachial artery were determined before and two hours after each intervention. Endothelium-independent vaso-
dilation (NMD) was measured 10 min after FMD by sublingual application of nitroglycerin spray (0.4 mg) before 
and after each intervention. Baseline diameter was assessed for 1 min, and the increase in diameter of the brachial 
artery after application of nitroglycerin was measured for 9 min.
Blood parameters. For cardiovascular risk assessment, the following parameters were measured by con-
ventional laboratory methods: total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides (TG), C-reactive 
protein (CrP), lipoprotein(a), HbA1c, and homocysteine. Total cholesterol, LDL cholesterol, HDL cholesterol, 
triglycerides, and CrP were determined before and two hours after each intervention.
Composition of the interventions and determination of plasma levels of tea com-
pounds. Concentrations of the individual tea substances in the interventions were measured on a Waters 
Acquity UPLC (Waters, Milford, MA, USA). The equipment consists of a binary pump (BSM), an autosam-
pler (SM) cooled at 10 °C, a column oven (CM) set at 40 °C, a diode array detector (PDA) scanning from 
190 to 500 nm, and an Acquity TQD triple-quadrupole mass spectrometer with an electrospray interface. 
A Waters BEH phenyl column (50 mm x 2.1 mm, 1.7 µm) with a VanGuard precolumn was employed at a 
flow rate of 0.6 ml/min. The eluents acetonitrile/0.1% formic acid (A) and water/0.1% formic acid (B) were 
run with the following gradient: 0 min: 6% A; 1.5 min 13% A; 2.3–3.3 min: 100% A; 4.3–5.3 min: 6% A. Peak 
identity was confirmed by MS/MS. For quantification, authentic reference compounds were used (detec-
tion wavelength 278 nm) for external calibration. Liquid samples were adequately diluted, solid samples 
were dissolved with methanol/water (80/20), and filtered through 0.2 µm Chromafil RC-20/15 MS filters 
(Macherey-Nagel, Düren, Germany).
Plasma levels of green tea catechins were measured as previously described13. To determine the levels of free 
(unconjugated) catechins, all samples were analysed in parallel, with omission of enzymatic hydrolysis. Plasma 
levels of caffeine and theobromine were determined as described36, with slight modifications: 40 µl of 20% aque-
ous perchloric acid were added to 100 µl of thawed plasma samples and centrifuged. The supernatant was injected 
into the UHPLC system (as described above). For external calibration, authentic reference compounds were used 
(detection wavelength 278 nm).
Statistical analysis. For this exploratory pilot study, comparisons of parameters between the four inter-
ventions water, EGCG, GTE, and green tea were performed by repeated measures ANOVA. After overall sta-
tistical differences between treatments (p < 0.05), this was followed by post hoc Bonferroni correction to adjust 
for multiple testing. Pairwise comparisons of parameters before and after interventions within treatments were 
performed using paired t-tests or Wilcoxon tests (for non-Gaussian distributions). Correlations between plasma 
levels of individual tea substances and FMD were calculated by using Spearman’s rho coefficient. All statistical 
tests were two-sided, with the level of significance accepted at p < 0.05. Statistical analysis was performed using 
SPSS, release 22.0 (SPSS, Inc., Chicago, IL, USA). Values are given as means±SD.
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